| Q71262856 | A sensitive radioimmunoassay for vincristine and vinblastine |
| Q37932369 | Antineoplastic drugs in 1990. A review (Part II). |
| Q39496661 | Antineoplastic drugs: clinical pharmacology and therapeutic use. |
| Q70825542 | Antitubulin activity of vinblastine and vincristine. Clinical implications of the radial segmentation test |
| Q41493539 | Biochemical effects of vindesine |
| Q70900586 | British Association for Cancer Research 22nd Annual general meeting. 13-15 April 1981. Abstracts |
| Q42831422 | BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy |
| Q34707699 | Clinical pharmacokinetics of commonly used anticancer drugs. |
| Q68579761 | Clinical pharmacokinetics of intravenously injected tritiated vinzolidine |
| Q41675267 | Clinical pharmacokinetics of vindesine |
| Q69988397 | Clinical pharmacology of vinzolidine |
| Q41849744 | Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine |
| Q35994294 | Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas |
| Q33767004 | Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice |
| Q33900622 | Diminished antiviral effect of human interferon in the presence of therapeutic concentrations of antineoplastic agents |
| Q40104510 | Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs |
| Q39548978 | Guide to drug dosage in renal failure |
| Q36045431 | In vitro sensitivity of human ovarian tumours to chemotherapeutic agents |
| Q70733022 | Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes |
| Q37476694 | Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature |
| Q41242202 | Metformin Sensitizes Leukemia Cells to Vincristine via Activation of AMP-activated Protein Kinase |
| Q42270305 | Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors |
| Q41202040 | Oral VP-16-213 in advanced bronchogenic carcinoma |
| Q42668077 | Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys |
| Q70583846 | Pharmacokinetics of vindesine bolus and infusion |
| Q40164346 | Pharmacology, Clinical Efficacy and Adverse Effects of Vindesine Sulfate, A New Vinca Alkaloid |
| Q35691002 | Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia |
| Q34551578 | The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics |
| Q33476929 | Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma |
| Q27000078 | Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine |
| Q37092954 | Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. |
| Q36072490 | Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo |
| Q40734879 | Vincristine infusion. A phase I study |